Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. - Wikidata - wikimedia - TriplyDB

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

http://www.wikidata.org/entity/Q34166617

about

Alleviating anemia and thrombocytopenia in myelofibrosis patients.Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management.Splanchnic vein thrombosis in myeloproliferative neoplasms.The evolution and clinical relevance of prognostic classification systems in myelofibrosis.Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.Azygos continuation of the caudal vena cava with segmental aneurysm, lung lobe torsion and pulmonary thromboembolism in a dog.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

P2860

Q33430113-4E6A1AB2-696E-4C6B-BEFA-C9DBB60AA4A3 Q38100371-1BEB81DA-E08A-4AFF-B2BD-6EE21FCA61BA Q38121635-FF9A3BFC-20B6-4172-BC0E-FF2542B32597 Q38683077-9EAFACD6-A3BC-489E-B3CD-25F1499D7A2A Q47785142-060E0819-87E0-4040-97B3-B2E57D0F3586 Q49315159-A5F180DA-A43E-4E10-9BCB-158D1A38ED7A Q53111428-7282E34B-62B1-437A-A79F-6B2E415EACD3

P2860

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

http://www.wikidata.org/entity/Q34166617

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@ast

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@en

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@nl

type

label

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@ast

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@en

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@nl

prefLabel

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@ast

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@en

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@nl

P1433

Q34166617-FDE4386E-B42E-4493-A7EA-8F76FEA6F757

P1476

Q34166617-4F1C9401-4018-4D31-BD03-A4D21755FC45

P2093

Q34166617-251ED66C-DE76-4B90-BA7F-03DA4DC35217

Q34166617-8F2081E1-1177-494D-8B43-34E380E56D91

Q34166617-CC97C543-C0D1-4B42-B006-5C3E7FBC9C71

Q34166617-FDB04A69-189A-40A8-9CE3-3A735CB18983

P2860

Q34166617-265B9723-311D-4CBC-BA92-0741B9745224

Q34166617-29F29DAC-6585-4DC1-883C-2BE73C85FCD3

Q34166617-437FE6F2-9657-4EB2-A23D-9266FCB59AA0

Q34166617-444CFA39-2863-41E0-9CF0-3143E42CC78A

Q34166617-4F9A0548-751D-496D-B804-490EC8AE6B40

Q34166617-638737A1-300C-42A4-AA9B-45547682C3DB

Q34166617-67C0B9E8-3390-47DB-9950-ABC77CFBAEC2

Q34166617-6F34A38D-C26C-4345-A82A-B33118305C44

Q34166617-8CF013B1-1EEA-4B94-8F42-00D9535A478D

Q34166617-94A33177-D6A8-4A88-BCB5-2311DCA0111D

P304

Q34166617-F65F2153-F736-4382-AF57-1AB56AE2F121

P31

Q34166617-8654281D-019D-4B87-BACC-CDFF7CCE2BBE

P356

Q34166617-3AE31882-7459-4E63-B948-E1D0319E8C2D

P433

Q34166617-3B326B2A-E897-4B46-AD98-8290037EB62A

P478

Q34166617-84241275-2F47-44AC-BAEA-7B6188634843

P50

Q34166617-D0C6E045-7977-46E7-87B3-086320262B42

P577

Q34166617-EA0D315A-83B7-4FB9-B321-DC72C5981F65

P5875

Q34166617-BF95E7AD-F530-4078-AB9C-A6F3C067FF33

P698

Q34166617-8FC1D33C-0C1D-4F9E-96A5-6E581E4E6E81

P921

Q34166617-E4DB3465-56AF-43A1-8EF2-D534EE8F1C06

P932

Q34166617-9F7F0E23-2C94-4783-BED7-AEA47B83FB3C

P356

HAEMATOL.2010.025064

P1433

P1476

Thrombosis in myelofibrosis: p ...... st venous events are provoked.

@en

P2093

Animesh Pardanani

http://www.w3.org/2001/XMLSchema#string

Michelle Ann Elliott

http://www.w3.org/2001/XMLSchema#string

Susan M Schwager

http://www.w3.org/2001/XMLSchema#string

Terra L Lasho

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of low-dose aspirin in polycythemia vera

The World Health Organization (WHO) classification of the myeloid neoplasms

Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.

Cancer, clots and consensus: new understanding of an old problem.

Prevention of venous thromboembolism in hospitalized patients with cancer.

JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis.

P304

1788-1791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2010.025064

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

95

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47156389

http://www.w3.org/2001/XMLSchema#string

P698

20884719

http://www.w3.org/2001/XMLSchema#string

P921

P932

2948107

http://www.w3.org/2001/XMLSchema#string